169 related articles for article (PubMed ID: 29662627)
1. Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway.
Adimonye A; Stankiewicz E; Kudahetti S; Trevisan G; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
Oncotarget; 2018 Mar; 9(22):16074-16086. PubMed ID: 29662627
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer.
Adimonye A; Stankiewicz E; La-Touche S; Kudahetti S; Trevisan G; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
PLoS One; 2018; 13(6):e0198905. PubMed ID: 29902261
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer.
Adimonye A; Stankiewicz E; Touche S; Kudahetti S; Tinwell B; Corbishley C; Lu YJ; Watkin N; Berney D
Urology; 2018 Jul; ():. PubMed ID: 30031830
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
6. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphatidylinositol 3-kinase catalytic subunit alpha by miR-203a-3p reduces hypertrophic scar formation via phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway.
Zhao S; Liu H; Wang H; He X; Tang J; Qi S; Yang R; Xie J
Burns Trauma; 2024; 12():tkad048. PubMed ID: 38179473
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
9. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.
Stankiewicz E; Prowse DM; Ng M; Cuzick J; Mesher D; Hiscock F; Lu YJ; Watkin N; Corbishley C; Lam W; Berney DM
PLoS One; 2011 Mar; 6(3):e17517. PubMed ID: 21407808
[TBL] [Abstract][Full Text] [Related]
10. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
11. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.
Sewell A; Brown B; Biktasova A; Mills GB; Lu Y; Tyson DR; Issaeva N; Yarbrough WG
Clin Cancer Res; 2014 May; 20(9):2300-11. PubMed ID: 24599934
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
[TBL] [Abstract][Full Text] [Related]
13. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
17. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and biological analysis of
Razia S; Nakayama K; Nakamura K; Ishibashi T; Ishikawa M; Minamoto T; Iida K; Otsuki Y; Nakayama S; Ishikawa N; Kyo S
Exp Ther Med; 2019 Sep; 18(3):2278-2284. PubMed ID: 31410178
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
[TBL] [Abstract][Full Text] [Related]
20. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
